| Bioactivity | (E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker. |
| Target | β blocker |
| In Vivo | The purpose of the present study is to explore the pharmacological significance of Alprenoxime peripheral /βblocking activity in a non-rodent animal model. Interspecies scaling considerations predict that the doses selected in this study (1 and 5 mg/kg) are pharmacologically comparable or greater than doses used in rodent studies (2 and 6 mg/kg). More importantly, the prolonged ocular antihypertensive effects that are shown with 1% ophthalmic solutions indicate that the i.v. dose tested in the present study is likely to be more than two orders of magnitude greater than probable therapeutic doses[1]. |
| Name | (E)-Alprenoxime |
| CAS | 125720-84-5 |
| Formula | C15H22N2O2 |
| Molar Mass | 262.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Polgar P, et al. Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Life Sci. 1995;56(14):1207-13. |